SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced its fourth quarter results. announced that it would be released. and before the market open on Thursday, March 21, 2024, he will announce full-year 2023 financial results.
An accompanying conference call will be hosted by Chief Executive Officer Dwight Gorham and President and Chief Financial Officer Andre Godin to discuss the results and provide business updates. Conference call and webcast details are below.
Fourth quarter and full year 2023 results conference call details:
|
date: |
Thursday, March 21, 2024 |
|
time: |
8:30 a.m. (Eastern Standard Time) |
|
Live call: |
1-888-506-0062 (Canada and USA) |
|
access code: |
321268 |
This conference call will be broadcast live and archived under “Webcast” in the “Investors” section of our website at www.intelgenx.com.
About Intel Genx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
Superior film technology from IntelGenx, including VersaFilm®DINTEC™solid film® and transdermal VevaDerm™, enabling the next generation of medicines that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many treatment conditions.
IntelGenx's highly skilled team provides comprehensive pharmaceutical services to our pharmaceutical partners, including research and development, analytical method development, clinical monitoring, and intellectual property and regulatory services. IntelGenx's state-of-the-art manufacturing facility provides full service, offering lab scale to pilot scale and commercial scale production. For more information, please visit www.intelgenx.com.
Forward-looking information and statements
This document may contain forward-looking information regarding IntelGenx's results of operations and business prospects that involve significant risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements regarding IntelGenx's plans, objectives, expectations, strategies, intentions, or other characteristics of future events or circumstances, and generally include, but are not limited to, Identified by the words “expected,” “anticipated,” and “.” “intends,” “plans,” “believes,” “seeks,” “estimates,” “could,” “will” and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. These forward-looking statements involve a number of risks and uncertainties that could cause IntelGenx's actual results to differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” in IntelGenx's Annual Report on Form 10-K. It will not be. This report is filed with the U.S. Securities and Exchange Commission and is available at www. sec.gov and filed with Canadian securities regulators at www.sedarplus.ca. IntelGenx undertakes no obligation to update any such forward-looking statements.
sauce: Intel Genx Technologies Corp.
For IntelGenx:
stephen kilmer
PR for investors
(647) 872-4849
stephen@kilmerlucas.com
or
Andre Godin, CPA, California
President and CFO
Intel Genx Corp.
(514) 331-7440 extension 203
andre@intelgenx.com
